BRISTOL MYERS SQUIBB

Jake Nichols, a pharmacist in recovery, highlights the challenges of substance use disorders in the profession. A phase 3 trial shows positive results for obinutuzumab in treating lupus nephritis. The FDA approves xanomeline and trospium chloride for schizophrenia, marking a new treatment option. Chronic pain in youth is linked to higher anxiety and depression, according to a study. Novo Nordisk's CEO agrees to negotiate lower list prices for semaglutide drugs with PBMs.

US FDA approves Cobenfy, the first new schizophrenia treatment in decades, targeting cholinergic receptors instead of dopamine. Developed by Bristol Myers Squibb, Cobenfy offers a new alternative to existing antipsychotic medications, with potential to significantly reduce symptoms and side effects.

Nemolizumab therapy showed continuous improvements in atopic dermatitis symptoms up to 56 weeks, with 47% achieving clear or almost clear skin and 73% improving EASI scores by 75%. Nemolizumab, an IL-31 receptor antagonist, demonstrated a favorable safety profile with no unexpected adverse events, positioning it as a valuable long-term treatment option for atopic dermatitis.

Isatuximab and lenalidomide (ISA-LEN) combination showed a 94% overall response rate after 18 cycles in high-risk smoldering multiple myeloma patients, with 97.1% 2-year progression-free survival. The treatment was well-tolerated, with common grade ≤2 treatment-related adverse events including leukocytopenia and lymphopenia.

Immunomodulatory agents, monoclonal antibodies, bispecific antibodies, and CAR T-cell therapy have transformed multiple myeloma treatment. Despite improvements, MM remains incurable, prompting research into protein degradation and immune system activation. The triSpecific antibody JNJ-79635322 targets BCMA, GPRC5D, and CD3, showing promise in preclinical trials. Other approaches include BCMA-targeting ADCs like belantamab mafodotin and small molecule E3 ligase modulators like mezigdomide, aiming to enhance immunotherapies and prolong patient survival.

Immunotherapies are crucial for multiple myeloma (MM) but face resistance and relapse. Proteasome inhibitors (PIs) and targeted therapies like BCL2 and BRAF/MEK inhibitors offer alternatives. Clonal evolution and subclonal mutations drive disease progression. Combination therapies, including melphalan, increase mutational load. Resistance to lenalidomide and anti-CD38 antibodies is common, but combinations like carfilzomib, daratumumab, and dexamethasone improve progression-free survival (PFS). BCMA-targeted antibody-drug conjugates (ADCs) show promise. Targeted inhibitors for BCL2, BRAF/MEK, and NSD2 benefit refractory patients. Despite clinical promise, access to these therapies is limited, highlighting the need for cost-effective treatments and innovative approaches.

Bristol Myers Squibb announces FDA approval of COBENFY™ (xanomeline and trospium chloride), the first new pharmacological approach to treat schizophrenia in decades, targeting M1 and M4 receptors without blocking D2 receptors. Supported by the EMERGENT clinical program, COBENFY demonstrated significant symptom reduction in schizophrenia patients.

FDA approved Cobenfy, a new schizophrenia treatment targeting cholinergic receptors, offering an alternative to traditional antipsychotics with fewer side effects. Expected to be available in late October, it costs $1,850 per month.

The FDA approved Cobenfy, a new schizophrenia drug with fewer side effects, marketed by Bristol Myers Squibb. Unlike traditional dopamine-focused drugs, Cobenfy targets muscarinic receptors, reducing negative symptoms like apathy. Available from October at $1,850/month, its long-term safety and efficacy remain uncertain.

Zvi offers legal, retirement, and estate planning services in New York, including cash management and Bitcoin services. He is The Claw of The Lava Empire and an Amazon Influencer. This article, written by Zvi, discusses his beneficial long positions in BMY and MRK shares. Seeking Alpha's disclosure emphasizes that past performance does not guarantee future results and that the views expressed may not reflect those of Seeking Alpha as a whole.